Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

被引：0

作者：

Sandhu, Karamjeet S. ^{[1
]}

Quy Huynh-Tran ^{[1
]}

Cooper, Elise Elise ^{[1
]}

Zhang, Jianying ^{[2
]}

Palmer, Joycelynne ^{[2
]}

Tsai, Ni-Chun ^{[2
]}

Thomas, Sandra ^{[3
]}

Robbins, Marjorie ^{[3
]}

Aribi, Ahmed ^{[1
]}

Salhotra, Amandeep ^{[1
]}

Mei, Mathew ^{[1
]}

Cai, Ji-Lian ^{[4
]}

Spielberger, Ricardo ^{[4
]}

Koller, Paul ^{[1
]}

Aldoss, Ibrahim ^{[1
]}

Stein, Anthony ^{[1
]}

Marcucci, Guido ^{[1
]}

Budde, L. Elizabeth ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Computat & Quantitat Med BRI, 1500 E Duarte Rd, Duarte, CA 91010 USA

[3] City Hope Natl Med Ctr, Clin Translat Program Dev, 1500 E Duarte Rd, Duarte, CA 91010 USA

[4] Kaiser Permanente BMT Program, Los Angeles, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

ALL; acute lymphoblastic leukemia; blinatumomab; pembrolizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ALL-440

引用

页码：S276 / S276

页数：1

共 50 条

[21] Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
Rafei, Hind
Kantarjian, Hagop M.
Sasaki, Koji
Short, Nicholas J.
Ravandi, Farhad
Huang, Xuelin
Khoury, Joseph D.
Wang, Sa A.
Jorgensen, Jeffrey L.
Yin, C. Cameron
Khouri, Issa F.
Kebriaei, Partow
Jain, Nitin
Takahashi, Koichi
Dabaja, Bouthaina S.
Verstovsek, Srdan
Kadia, Tapan M.
Paul, Shilpa
Rausch, Caitlin R.
Garcia-Manero, Guillermo
Wierda, William G.
DiNardo, Courtney D.
Daver, Naval
Montalban-Bravo, Guillermo
Yilmaz, Musa
Nasnas, Patrice
Khouri, Rita
Kwari, Monica
Jacob, Jovitta
Rostykus, Meagan
Garris, Rebecca
Konopleva, Marina
O'Brien, Susan M.
Jabbour, Elias
BLOOD, 2020, 136
[22] Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)
Locatelli, Franco
Zugmaier, Gerhard
Mergen, Noemi
Bader, Peter
Jeha, Sima
Schlegel, Paul-Gerhardt
Bourquin, Jean-Pierre
Handgretinger, Rupert
Brethon, Benoit
Rossig, Claudia
Kormany, William
Viswagnachar, Puneeth
Chen-Santel, Christiane
BLOOD, 2020, 136
[23] Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
von Stackelberg, Arend
Locatelli, Franco
Zugmaier, Gerhard
Handgretinger, Rupert
Trippett, Tanya M.
Rizzari, Carmelo
Bader, Peter
O'Brien, Maureen M.
Brethon, Benoit
Bhojwani, Deepa
Schlegel, Paul Gerhardt
Borkhardt, Arndt
Rheingold, Susan R.
Cooper, Todd Michael
Zwaan, Christian M.
Barnette, Phillip
Messina, Chiara
Michel, Gerard
DuBois, Steven G.
Hu, Kuolung
Zhu, Min
Whitlock, James A.
Gore, Lia
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4381 - +
[24] Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
Grupp, Stephan A.
Maude, Shannon L.
Rives, Susana
Baruchel, Andre
Boyer, Michael W.
Bittencourt, Henrique
Bader, Peter
Buchner, Jochen
Laetsch, Theodore W.
Stefanski, Heather
Myers, Gary Douglas
Qayed, Muna
Pulsipher, Michael A.
De Moerloose, Barbara
Yanik, Gregory A.
Davis, Kara L.
Martin, Paul L.
Nemecek, Eneida R.
Peters, Christina
Krueger, Joerg
Balduzzi, Adriana
Boissel, Nicolas
Mechinaud, Francoise Marie
Leung, Mimi
Eldjerou, Lamis K.
Yi, Lan
Mueller, Karen Thudium
Bleickardt, Eric
Hiramatsu, Hidefumi
BLOOD, 2018, 132
[25] Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Gore, Lia
Locatelli, Franco
Zugmaier, Gerhard
Zwaan, Christian M.
Bhojwani, Deepa
Handgretinger, Rupert
Bader, Peter
O'Brien, Maureen M.
Trippett, Tanya M.
Brethon, Benoit
Rizzari, Carmelo
DuBois, Steven G.
Schlegel, Paul Gerhardt
Barnette, Phillip
Messina, Chiara
Hu, Kuolung
Mergen, Noemi
Fischer, Anja
Whitlock, James
von Stackelberg, Arend
BLOOD, 2014, 124 (21)
[26] A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS
Bassan, R.
Fumagalli, M.
Meloni, G.
Audisio, E.
Cascavilla, N.
Paolini, S.
Specchia, G.
Cerqui, E.
Mico, C.
Fabbiano, F.
Ronco, F.
Scattolin, A. M.
Perfetti, P.
Paoloni, F.
Vitale, A.
Vignetti, M.
Foa, R.
HAEMATOLOGICA, 2017, 102 : 199 - 199
[27] Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Li, Shiqi
Wang, Xinxin
Yuan, Zhongtao
Liu, Lin
Li, Yu
Liu, Jia
He, Jiaping
Li, Zhimin
Zhao, Wei
Ge, Jianning
Ni, Yajin
Shen, Lianjun
Cao, Wei
Zhang, Xi
Sersch, Martina
Wang, Sanbin
CANCER RESEARCH, 2022, 82 (12)
[28] Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
Nasnas, Cedric Christophe
Jabbour, Elias
Haddad, Fadi
Short, Nicholas James
Macaron, Walid
Zoghbi, Marianne
Nasr, Lewis Fady
Jain, Nitin
Almanza, Emmanuel
Sasaki, Koji
Ravandi, Farhad
Kebriaei, Partow
Huang, Xuelin
Garcia-Manero, Guillermo
Kadia, Tapan M.
Wang, Sa A.
Jacob, Jovitta
Garris, Rebecca
O'Brien, Susan M.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab
Goekbuget, Nicola
Kantarjian, Hagop
Brueggemann, Monika
Stein, Anthony
Bargou, Ralf C.
Dombret, Herve
Fielding, Adele K.
Heffner, Leonard
Rigal-Huguet, Francoise
Litzow, Mark
O'Brien, Susan
Zugmaier, Gerhard
Jia, Catherine
Maniar, Tapan
Huber, Birgit
Nagorsen, Dirk
Forman, Stephen J.
Topp, Max S.
BLOOD, 2014, 124 (21)
[30] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Giri, Pratyush
Patil, Sushrut
Ratnasingam, Sumita
Prince, H. Miles
Milliken, Samuel
Meijide, Javier Briones
Coyle, Luke
Van der Poel, Marjolein
Mulroney, Carolyn M.
Farooqui, Mohammed Z. H.
Wong, Hansen
Desai, Rajendra
Zugmaier, Gerhard
Mergen, Noemi
Cannell, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →